查詢結果分析
相關文獻
- Attenuation of Basilar Artery Spasm after Experimental Subarachnoid Hemorrhage in Rabbit by Potassium Channel Activator Cromakalim-A Preliminary Result
- 腦動脈瘤引起蜘蛛網膜下腔出血之急症處理
- 動脈瘤的蜘蛛網膜下腔出血
- 顱內動脈瘤破裂後引發之腦血管痙攣
- Management of Aneurysmal Subarachnoid Hemorrhage
- The Effect of Prostaglandin E [feb5] on vasoconstriction Induced by Extravasating Blood
- Treatment of Cerebral Vasospasm after Subarachnoid Hemorrhage--A Review
- 雷諾氏現象之簡介
- Severe Coronary Vasospasm during an Acute Myocardial Infarction with Cardiogenic Shock
- Predictors of Brachial Artery Spasm during Transradial Cardiac Catheterization
頁籤選單縮合
題 名 | Sirolimus Alleviates Experimental Subarachnoid Hemorrhage Induced Vasospasm=細胞內訊息下傳抑制物Sirolimus防止實驗性蜘蛛膜下腔出血引起的血管痙攣 |
---|---|
作 者 | 張志任; 關暟麗; 洪純隆; | 書刊名 | Medical Journal of South Taiwan |
卷 期 | 3:3 2007.12[民96.12] |
頁 次 | 頁126-131 |
分類號 | 416.29 |
關鍵詞 | 血管痙攣; Sirolimus; Vasospasm; Cd45; |
語 文 | 英文(English) |
中文摘要 | 細胞內訊息下傳抑制物(如Sirolimus)為一已知潛在的免疫抑制劑,迄今尚未被用來研究蜘蛛膜下腔出血引起的血管痙攣,目前的研究目標針對蜘蛛膜下腔出血引起的單核細胞免疫反應及Sirolimus對單核細胞免疫的影響。實驗對象為Sprague-Dawley大白鼠,誘發蜘蛛膜下腔出血後,非隨機性分成兩組,Sirolimus劑量的決定以先前的藥物動力學為準。單株免疫球蛋白(抗CD45)對白血球的染色作為評估Sirolimus對免疫反應的抑制;同時測量血管內徑面積。在使用Sirolimus一組,其血管內徑通透率約92%,相對於對照組的69.3%,明顯有意義的增加(p<0.01);在單株免疫球蛋白反應中,抗CD45白血球的量化反應值上,Sirolimus組及對照組比值為30.3±?比66.6±5.4/200μm^2。結論:Sirolimus藉由對蜘蛛膜下腔出血引起的延遲性免疫反應,而達成阻止或減缓腦血管的痙攣。雖然其真正的機轉並無法從本研究中,窺得全貌,但本實驗除證實免疫抑制劑Sirolimus能有效抑制血管的痙攣,也提供訊息免疫反應在蜘蛛膜下腔出血引起的延遲性腦血管的痙攣伴演一重要角色。 |
英文摘要 | Background: Sirolimus is known to be a potent immunosupressive agent. However it has not been previously investigated in the management of cerebral vasospasm following subarachnoid hemorrhage. Methods: The rodent femoral artery model of vasospasm was employed. 20 male Sprague-Dawley rats (250-350g) were randomly assigned to 2 different groups. Dosages were selected based upon pilot data and drug pharmacokinetic studies. Vasospasm was evaluated at post-hemorrhage day 8 (the point of peak constriction in this model). Vasospasm was evaluated by calculation of cross-sectional vessel area and radial wall thickness using computerized video analysis and was expressed as percent lumen potency (ratio of blood exposed to non-blood exposed vessel). Monoclonal CD45 immunostaining for leukocyte was evaluated (x200). Results: Significant vasospasm was noted in the vehicle treated group (lumen potency 69.3%, p≤0.01). Insignificant vasospasm was noted in the Sirolimus treated groups (Lumen potency, 92.3% for the Sirolimus groups, p=0.41). Additionally, infiltration of inflammatory cells was qualitatively less in the sirolimus treated groups compared to the vehicle treated group. Quantification of CD45 positive leukocyte infiltration is prominent in the control hemorrhage site of the vehicle treatment group (mean 30.3±3.2 vas. 66.6±5A in 200 μm2). Conclusions: Administration of cell downstream signal inhibitor sirolimus, extensively decreased CD45 positive leukocytes, devoid experimental post-hemorrhagic vasospasm and is meritorious of further investigation. This study supports a role for inflammation in the development of vasospasm and anti-inflammatory agent could play a role in the therapeutics in the future study. |
本系統中英文摘要資訊取自各篇刊載內容。